<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168186">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01908699</url>
  </required_header>
  <id_info>
    <org_study_id>BPS-314d-MR-PAH-302</org_study_id>
    <nct_id>NCT01908699</nct_id>
  </id_info>
  <brief_title>Beraprost-314d Added-on to Tyvaso® (BEAT)</brief_title>
  <acronym>BEAT</acronym>
  <official_title>A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lung Rx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lung Rx</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, double-blind, randomized, placebo-controlled Phase 3 study, to assess
      the efficacy and safety of BPS-314d-MR when added-on to inhaled treprostinil (Tyvaso®)in
      patients with pulmonary arterial hypertension.

      Patients new to Tyvaso, will enter a run-in period on inhaled treprostinil until 90 days of
      experience is achieved to ensure drug tolerability before enrolling in the study.

      Treatment groups consist of one active and one placebo group. Subjects will be randomly
      allocated in a 1:1 ratio to one of the two treatment groups.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to clinical worsening defined as time from randomization to the first of any of the events described below.</measure>
    <time_frame>Assessed every 4 weeks for first 12 weeks after randomization and assessed every 12 weeks upto 144 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Clinical worsening events:
Death (all causes)
Hospitalization due to worsening PAH
Disease progression
Unsatisfactory long-term clinical response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>6 minutes Walk Distance</measure>
    <time_frame>Assessed every 4 weeks for first 12 weeks after randomization and assessed every 12 weeks upto 144 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg Dyspnea Score</measure>
    <time_frame>Assessed every 4 weeks for first 12 weeks after randomization and assessed every 12 weeks upto 144 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Functional Class</measure>
    <time_frame>Assessed every 4 weeks for first 12 weeks after randomization and assessed every 12 weeks upto 144 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NT-pro-BNP levels</measure>
    <time_frame>Assessed every 4 weeks for first 12 weeks after randomization and assessed every 12 weeks upto 144 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed by adverse events, physical examination, vital signs, clinical laboratory parameters, and electrocardiogram findings.</measure>
    <time_frame>Assessed every 4 weeks for first 12 weeks after randomization and assessed every 12 weeks upto 144 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety will be assessed by adverse events, physical examination, vital signs, clinical laboratory parameters, and electrocardiogram findings.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Beraprost Sodium 314d Modified Release Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beraprost Sodium 314d Modified Release Tablets</intervention_name>
    <description>Available as 15 μg tablets for oral,  1 or 2 tablets four times daily (QID) administration</description>
    <arm_group_label>Beraprost Sodium 314d Modified Release Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, age 18 to 80 years (inclusive).

          2. Established diagnosis of pulmonary arterial hypertension that is either idiopathic or
             familial PAH, collagen vascular disease associated PAH, PAH associated with HIV
             infection, PAH induced by anorexigens/toxins, or PAH associated with repaired
             congenital systemic-topulmonary shunts (repaired ≥5 years).

          3. If HIV positive, has CD4 lymphocyte count ≥200 cells/mm3 within 30 days of Baseline
             Visit and is receiving current standard of care anti-retroviral or other effective
             medication.

          4. Showing signs of deterioration on inhaled treprostinil or having a less than optimal
             response to inhaled treprostinil treatment.

          5. Able to walk unassisted (oxygen use allowed).

          6. A 6-Minute Walk distance (6MWD) of ≥ 100 meters at the Screening Visit.

          7. Previous (within five years prior to the Baseline visit) right heart cardiac
             catheterization(RHC) with findings consistent with PAH, specifically mean Pulmonary
             Arterial Pressure(PAPm) ≥25 mmHg (at rest), Pulmonary Capillary Wedge Pressure (PCWP)
             (or left ventricular end diastolic pressure) ≤15 mmHg, and Pulmonary Vascular
             Resistance (PVR)&gt;3 mmHg/L/min.

          8. Within five years prior to the Baseline visit, chest radiograph consistent with PAH.

          9. Echocardiography with results consistent with PAH and the absence of any clinically
             significant left heart disease (e.g. mitral valve stenosis, myocardial infarction,
             etc.).

         10. Pulmonary function tests conducted within 6 months before or during the Screening
             period to confirm the following:

               1. Total lung capacity (TLC) is at least 60% (predicted value) assessed by whole
                  body plethysmography

               2. Forced expiratory volume at one second (FEV1) of at least 50% (predicted value)

         11. WHO functional class III to IV

         12. Subjects receiving PAH therapies (i.e. ERAs, PDE-5 inhibitors) must be stable on
             their current dose for at least 30 days prior to Baseline. Discontinuation or dose
             changes of anticoagulants and/or dose change of diuretics are allowed.

         13. Must have received a stable dose of inhaled treprostinil for at least 30 days prior
             to Baseline. Those initiating therapy at the time of screening must complete 90 days
             of inhaled treprostinil treatment and any concurrent background therapies before the
             Baseline visit to be eligible for randomization into the study.

         14. Women of child-bearing potential (defined as less than 1 year post-menopausal and not
             surgically sterile) must be practicing abstinence or using two highly effective
             methods of contraception (defined as a method of birth control that result in a low
             failure rate, i.e., less than 1% per year, such as approved hormonal contraceptives,
             barrier methods [such as a condom or diaphragm] used with a spermicide, or an
             intrauterine device). Subject must have a negative pregnancy test at the Screening
             and Baseline visits.

         15. Willing and able to comply with study requirements and restrictions.

        Exclusion Criteria:

          1. The subject is pregnant or lactating.

          2. The subject previously received beraprost or BPS-314d (i.e., BPS-IR, BPS-MR or
             BPS-314d-MR)

          3. Has pulmonary venous hypertension, pulmonary veno-occlusive disease, pulmonary
             capillary hemangiomatosis, or chronic thromboembolic pulmonary hypertension.

          4. Has a positive vasoreactive response (a reduction of pulmonary artery pressure ≥10 Hg
             mm to ≤ 40 mmHg with increased or unchanged cardiac output) to acute pulmonary
             vasodilator testing or failure to respond to calcium channel blocker therapy within
             the past 5 years.

          5. Has a history of interstitial lung disease, unless subject has collagen vascular
             disease and has had pulmonary function testing conducted within 6 months of the
             Baseline visit demonstrating a total lung capacity ≥70% of predicted.

          6. Has a history of obstructive lung disease, unless subject has had pulmonary function
             testing conducted within 6 months of the Baseline visit demonstrating a forced
             expiratory volume in 1 second (FEV1) of ≥ 50% of predicted.

          7. Has an ongoing hemorrhagic condition (e.g., upper digestive tract hemorrhage,
             hemoptysis,etc.), or has a pre-existing condition that, in the Investigator's
             judgment, may increase the risk for developing hemorrhage during the study (e.g.,
             hemophilia). Transient hemorrhage(e.g., epistaxis, normal menstrual bleeding,
             gingival bleeding, hemorrhoidal bleeding, etc.)will not preclude enrollment.

          8. Has received any investigational drug, device or therapy within 30 days prior to the
             Baseline visit or is scheduled to receive another investigational drug, device or
             therapy during the course of the study.

          9. Has any musculoskeletal disease or any other disease that would significantly limit
             ambulation.

         10. Has any form of unrepaired or recently repaired (&lt; 5 years) congenital
             systemic-topulmonary shunt other than patent foramen ovale.

         11. Documented history or current evidence of ischemic heart disease.

         12. History of left sided myocardial disease as evidenced by a mean PCWP (or a left
             ventricular end diastolic pressure) &gt; 15 mmHg or left ventricular ejection fraction &lt;
             40% as assessed by either multigated angiogram, angiography or echocardiography, or
             left ventricular shortening fraction &lt;22% as assessed by echocardiography. Note that
             subjects in whom abnormal left ventricular function is attributed entirely to
             impaired left ventricular filling due to the effects of right ventricular overload
             (i.e., right ventricular hypertrophy and/or dilatation) will not be excluded.

         13. Has creatinine clearance &lt;30 (using the Crockroft-Gault formula) or requires
             hemodialysis.

         14. Has Childs-Pugh class C liver cirrhosis.

         15. Has had previous atrial septostomy.

         16. Any other clinically significant illness that, in the opinion of the Investigator,
             might put the subject at risk of harm during the study or might adversely affect the
             interpretation of the study data.

        No waivers to entry criteria are allowable in this study; however, subjects who are
        initially ineligible for this study may be reassessed for eligibility after consultation
        with the Sponsor.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tracy Newbold, PMP</last_name>
    <phone>301-608-9292</phone>
    <phone_ext>1988</phone_ext>
    <email>tnewbold@lungllc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leigh Powell, RN, BSN, MSN, CCRC</last_name>
      <phone>205-975-9859</phone>
      <email>leigh83@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Bourge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allianz Research Institute Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kay L Pernia</last_name>
      <phone>714-887-0600</phone>
      <email>kay.pernia@allianzresearch.com</email>
    </contact>
    <investigator>
      <last_name>David Pham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco - Fresno</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Garcia, CCRP</last_name>
      <phone>559-499-6637</phone>
      <email>sgarcia@fresno.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Vijay Balasubramanian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Thrasher, BS, CCRC</last_name>
      <phone>858-657-7127</phone>
      <email>mthrasher@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Hyong Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Pulmonary Medicine</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Gastauer</last_name>
      <phone>760-778-7799</phone>
      <email>mgastauer@palmtreeclinical.com</email>
    </contact>
    <investigator>
      <last_name>Learned Gonzales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joy Beckmann, RN</last_name>
      <phone>310-222-3560</phone>
      <email>jbeckmann@labiomed.org</email>
    </contact>
    <investigator>
      <last_name>Ronald Oudiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gentle Arnez</last_name>
      <phone>720-848-0480</phone>
      <email>gentle.arnez@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>David Badesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates P.C.</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Soltau, RN</last_name>
      <phone>303-703-2191</phone>
      <email>msoltau@southdenver.com</email>
    </contact>
    <investigator>
      <last_name>Ira Dauber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Kennedy</last_name>
      <phone>904-953-2255</phone>
      <email>kennedy.shannon@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Burger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minal Patel, M.B.B.S</last_name>
      <phone>904-244-1106</phone>
      <email>minal.patel@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Abubakr Bajwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida Research Solutions</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mejia-Gomez</last_name>
      <phone>954-986-3067</phone>
      <email>mmejiagomez@mitral.com</email>
    </contact>
    <investigator>
      <last_name>Julio Tallet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Miami Heart Specialists</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Jean-Mary</last_name>
      <phone>305-666-4633</phone>
      <phone_ext>254</phone_ext>
      <email>jjeanmary@smiamiheart.com</email>
    </contact>
    <investigator>
      <last_name>Javier Jimenez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cardiovascular Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Lee</last_name>
      <phone>813-944-8240</phone>
      <email>courtneyelee@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Joel Fernandez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Gillespie, RN</last_name>
      <phone>404-712-8204</phone>
      <email>jane.gillespie@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Micah Fisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Critical Care of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dee Porter</last_name>
      <phone>404-564-3022</phone>
      <email>dee.porter@northside.com</email>
    </contact>
    <investigator>
      <last_name>Paul Boyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Burks, CRC</last_name>
      <phone>770-745-1404</phone>
      <phone_ext>2</phone_ext>
      <email>kristin.burks@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Chad Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gwinnett Biomedical Research</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chevy Brown, MPH, CCRC</last_name>
      <phone>678-942-5986</phone>
      <email>cbrown@gwinnettresearch.com</email>
    </contact>
    <investigator>
      <last_name>Paul Weinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donneea Edwards-Moore</last_name>
      <phone>773-702-6049</phone>
      <email>dedwards@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Mardi Gomberg-Maitland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Suburban Lung Associates</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Joseph</last_name>
      <phone>847-981-3660</phone>
      <email>mary.joseph@sublung.com</email>
    </contact>
    <investigator>
      <last_name>Meena Murugappan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Health and Hospitals Corporation</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Cole</last_name>
      <phone>630-873-3410</phone>
      <email>teresa.cole@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Maria Rosa Costanzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research Center</name>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <zip>46011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Lipps</last_name>
      <phone>765-298-2040</phone>
      <email>sheri.lipps@ecommunity.com</email>
    </contact>
    <investigator>
      <last_name>Saiful Kabir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University - Health Physicians</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Turk, RN, BSN</last_name>
      <phone>317-688-3847</phone>
      <email>eturk@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>William Harvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Robinson</last_name>
      <phone>502-587-8000</phone>
      <email>krobinson@kpadocs.com</email>
    </contact>
    <investigator>
      <last_name>John W McConnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lousiana State University Health Sciences Ctr - New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Lauto, RN, BSN</last_name>
      <phone>504-568-3451</phone>
      <email>plauto@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Bennett deBoisblanc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lioubov Poliakova</last_name>
      <phone>410-328-6885</phone>
      <email>lpoliako@medicine.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Myung Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Lawler, RN</last_name>
      <phone>617-525-9731</phone>
      <email>llawler@partners.org</email>
    </contact>
    <investigator>
      <last_name>Aaron Waxman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infinity Medical Research</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leora Fernandes</last_name>
      <phone>508-998-3041</phone>
      <email>lfernandes@infinitymedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Curtis Mello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Health Systems</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coleen Tessmar</last_name>
      <phone>248-964-8524</phone>
      <email>ctessmar@beaumont.edu</email>
    </contact>
    <investigator>
      <last_name>Samuel Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rutgers University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha N Ashton, APN-BC</last_name>
      <phone>973-972-4708</phone>
      <email>nashton@njms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Klapholz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haroon Chaudhry, MBBS</last_name>
      <phone>518-262-1542</phone>
      <email>chaudhh@mail.amc.edu</email>
    </contact>
    <investigator>
      <last_name>Boris Medarov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Byrnes, MD</last_name>
      <phone>516-663-9582</phone>
      <email>kbyrnes@winthrop.org</email>
    </contact>
    <investigator>
      <last_name>Shilpa DeSouza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Health Physicians, PC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beneta Parthiban, MS</last_name>
      <phone>315-234-0816</phone>
      <email>beneta.parthiban@CNYlungs.com</email>
    </contact>
    <investigator>
      <last_name>Sherif El Bayadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina, Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah McGee</last_name>
      <phone>919-966-2531</phone>
      <email>smcgee@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>H. James Ford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45627</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Banuelos, RN</last_name>
      <email>melissa.banuelos@uc.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Elwing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Haney</last_name>
      <phone>216-844-2381</phone>
      <email>david.haney@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Robert Schilz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Drake</last_name>
      <phone>614-293-4978</phone>
      <email>janice.drake@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Namita Sood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara A Gallagher, RN</last_name>
      <phone>215-955-8184</phone>
      <email>barbara.gallagher@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Scharf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Shoemaker, R.N</last_name>
      <phone>412-692-2769</phone>
      <email>shoeka@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Ishizawar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Smithson</last_name>
      <phone>401-444-9097</phone>
      <email>bsmithson@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>James Klinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anderson Pharmaceutical Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie N Tyson, CRC</last_name>
      <phone>864-965-0190</phone>
      <email>niki@andersonmedresearch.com</email>
    </contact>
    <investigator>
      <last_name>Charles Thompson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Quivers</last_name>
      <phone>214-645-6489</phone>
      <email>Jacqueline.Quivers@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Sonja Bartolome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Wardlow</last_name>
      <phone>254-724-7168</phone>
      <email>rwardlow@sw.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Spradley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Bullivant, CRC</last_name>
      <phone>757-388-4024</phone>
      <email>mmbulliv@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Michael Eggert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora St. Luke's Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulette Schauer, RN</last_name>
      <phone>414-649-5664</phone>
      <email>paulette.schauer@aurora.org</email>
    </contact>
    <investigator>
      <last_name>Dianne Zwicke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwuakee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Harris</last_name>
      <phone>414-955-7030</phone>
      <email>racharris@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Sikandar Ansari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>July 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beraprost</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
